Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
STOK

STOK - Stoke Therapeutics Inc Stock Price, Fair Value and News

$29.42-0.09 (-0.30%)
Market Closed

78/100

STOK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

78/100

STOK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$42.51

Target 3M

$32.29

Target 6M

$35.38

STOK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

STOK Price Action

Last 7 days

-0.3%

Last 30 days

-8.6%

Last 90 days

-7.2%

Trailing 12 Months

199.6%

STOK RSI Chart

STOK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

STOK Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

41.42

Price/Sales (Trailing)

8.17

EV/EBITDA

60.24

Price/Free Cashflow

32.09

STOK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$42.51

Target 3M

$32.29

Target 6M

$35.38

STOK Fundamentals

STOK Revenue

Revenue (TTM)

205.6M

Rev. Growth (Yr)

117.25%

Rev. Growth (Qtr)

-23.05%

STOK Earnings

Earnings (TTM)

40.6M

Earnings Growth (Yr)

-45.09%

Earnings Growth (Qtr)

-63.3%

STOK Profitability

EBT Margin

11.97%

Return on Equity

13.17%

Return on Assets

11.26%

Free Cashflow Yield

3.12%

STOK Investor Care

Shares Dilution (1Y)

7.84%

Diluted EPS (TTM)

0.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025190.9M199.9M205.6M0
202412.0M15.2M16.7M36.6M
202314.6M12.6M10.7M8.8M
202200012.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Stoke Therapeutics Inc

STOK
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.
 CEO
 WEBSITEstoketherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES117

Stoke Therapeutics Inc Frequently Asked Questions

STOK is the stock ticker symbol of Stoke Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Stoke Therapeutics Inc is 1.68 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check STOK's fair value in chart for subscribers.

The fair value guage provides a quick view whether STOK is over valued or under valued. Whether Stoke Therapeutics Inc is cheap or expensive depends on the assumptions which impact Stoke Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STOK.

As of Wed Jan 28 2026, STOK's PE ratio (Price to Earnings) is 41.42 and Price to Sales (PS) ratio is 8.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STOK PE ratio will change depending on the future growth rate expectations of investors.